Efficacy and safety of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24‐week, randomized, double‐blind, placebo‐controlled trial
Takashi Kadowaki; Nobuya Inagaki; Kazuoki Kondo; Kenichi Nishimura; Genki Kaneko; Nobuko Maruyama; Nobuhiro Nakanishi; Hiroaki Iijima; Yumi Watanabe; Maki Gouda
Author Information: Department of Diabetes and Metabolic Diseases, Graduate School of Medicine
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.